Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 90Carcinoma, Hepatocellular 29Neoplasm Metastasis 18Neoplasms 16Gastrointestinal Stromal Tumors 13Colonic Neoplasms 13Rectal Neoplasms 12Sarcoma 6Glioblastoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Liver Neoplasms 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Irinotecan 10Fluorouracil 10Leucovorin 9Bevacizumab 9Gemcitabine 8Paclitaxel 7Cisplatin 7Capecitabine 7Oxaliplatin 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Sorafenib 4Cetuximab 4pembrolizumab 3apatinib 3Radiotherapy 3Ocoxin 3Imatinib Mesylate 3Folfox protocol 3Everolimus 3Drug Therapy 3tislelizumab 2spartalizumab 2palbociclib 2entinostat 2encorafenib 2camrelizumab 2anlotinib 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Digestive System Neoplasms × regorafenib × Clear all
NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡